Jazz consensus expectations too low, says Lazard Capital Lazard Capital believes consensus expectations for Jazz Pharmaceuticals are too low following the company's Xyrem price increase last week. The firm keeps a Buy rating on the stock with an $87 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals price target raised to $130 from $110 at UBS UBS raised its price target on Jazz Pharmaceuticals to adjust its discount rate to reflect a change in risk premium. The firm notes the company's business continues to perform above expectations and expects additional business activities to diversify the company. Shares are Buy rated.